jRCT2031250615尚未招募不适用
A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema)
未提供0 个研究点目标入组 200 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Participants must meet the following criteria:
- •1.Are 18 years of age or older
- •2.Have clinical diagnosis of AD for at least 6 months prior to Day 1 and have diagnosis of AD confirmed by photographs
- •3.Have moderate to severe AD as defined by the following at screening and baseline visits:
- •Affected body surface area (BSA) greater than or equal to 10% and up to 60%;
- •Validated Investigator's Global Assessment (vIGA) greater than or equal to 3;
- •Eczema Area and Severity Index (EASI) greater than or equal to 16;
- •Peak Pruritis Numeric Rating Scale (PP-NRS) greater than or equal to 4 at screening and a weekly average of greater than or equal to 4 at baseline visit
- •4.Do not have a suitable prescribed medicine for AD.
- •5.Body Mass Index (BMI) of 17.5 to 40 kg/m2 and a total body weight greater than 45 kg (100 lbs)
排除标准
- •Participants must not meet the following criteria:
- •1.Have an infection that requires treatment
- •2.Have other skin conditions other than AD
- •3.Have severe uncontrolled asthma
- •4.Regular use (more than 2 visits per week) of a tanning booth or phototherapy for AD within 4 weeks of the screening visit
研究者
相似试验
尚未招募
不适用
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes (Enith2)OBESITY OR OVERWEIGHT AND TYPE 2 DIABETESjRCT20612500901,600
招募中
不适用
A PHASE IIb, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY WITH AN ACTIVE TREATMENT EXTENSION TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RO7837195 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISUlcerative ColitisjRCT204125014317
招募中
1 期
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS2023-504746-54-00Tranquis Therapeutics Inc.16
已完成
1 期
A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MES-1022 IN HEALTHY HUMAN SUBJECTS2023-503866-22-00Mesentech Inc.72
尚未招募
不适用
A Study to Find Out How Effective and Safe JNJ-88545223 is for the Treatment of Participants With Active Psoriatic Arthritis (a Long-term Inflammatory Arthritis) (VELOTA)Arthritis, PsoriaticjRCT2031250700240